Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The 1st phase of the study will assess the acute biochemical response of PTH, calcium and
phosphorus to orally administered doses of cinacalcet once (60mg) or twice (30mg x 2) per
day.
The 2nd phase of the study designed to evaluate the long term effects of cinacalcet on BMD
(bone mineral density)and the levels of PTH, calcium, phosphorus as well as its ability to
control secondary hyperparathyroidism without simultaneous administration of other vitamin D
compounds.